A medical cannabis company based in Perth (Australia) and Philadelphia (USA) receives $ 40 million in funding from US institutional investors following studies suggesting that its cannabis-based compound, CBD (Cannabidiol) could be used as a powerful new antimicrobial, including against “superbugs” (bacteria resistant to antibiotics) .
Botanix Pharmaceuticals chief executive, Matt Callahan, said investors in his institutional investment included several of the largest life sciences investors in the United States.
“In general, US institutional investors specializing in biotechnology do not invest in companies listed on the ASX. But we managed to attract 10 of them to the register,” Callahan told AAP. “We did not intend to go to raise capital, but the United States has a little interest in it.”
Callahan said the interest came after several studies revealed that cannabidiol has potent antibacterial properties.
CBD: natural antimicrobial
Studies at the Center of Queensland’s Institute for Molecular Bioscience indicated that cannabidiol :
“remarkably effective in killing a range of Gram-positive bacteria, with a potency similar to that of potent antibiotics”.
Methicillin-resistant Staphylococcus aureus (MRSA), known as “super bacteria” due to its resistance to the usual antibiotics, did not develop resistance to Botanix’s BTX 1801 antimicrobial product in 21 days of standardized repeat testing. industry.
CBD disrupts the vicious “biofilm” that surrounds bacteria and kills it in less than three hours, studies say.
Another study at Monash University’ has shown that Botanix AB 2367 antibacterial product works against the bacteria caused by diarrhea .
As part of this institutional investment, Botanix will issue 190 million shares at 21 cents per share. She also appointed a chief financial officer and a sales manager.
Botanix is testing 4 synthetic CBD capsules to treat acne, psoriasis and atopic dermatitis.You can learn more about using CBD for skin issues.
Institutional capital will support these studies and others needed before Botanix can begin Phase 3 (large scale) trials required to submit its products for approval.